NF2 and sarcoma: YAP/TAZ-TEAD inhibition triggered tumor regression in preclinical mouse models for mesothelioma3–7 and first data report clinical benefits for mesothelioma patients and patients with NF2 mutant sarcoma: ION537 (NCT04659096), VT3989 (NCT04665206), IK-930 88 NCT05228015) and IAG933 (NCT04857372).